Selected research
Industry Research
Live Attenuated Vaccines Industry Research Report 2026
Market perspective
The global Live Attenuated Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Live Attenuated Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Live Attenuated Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Live Attenuated Vaccines include Astellas Pharma, CSL, Serum Institute Of India, GlaxoSmithKline, Pfizer, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Live Attenuated Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Live Attenuated Vaccines Market by Company
Astellas Pharma
CSL
Serum Institute Of India
GlaxoSmithKline
Pfizer
Merck
Johnson & Johnson
Sanofi
Live Attenuated Vaccines Segment by Type
Bacterial
Viral
Live Attenuated Vaccines Segment by Application
Research Institutes
Hospitals
Clinics
Others
Live Attenuated Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Live Attenuated Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Live Attenuated Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bacterial
- Viral
Applications
- Research Institutes
- Hospitals
- Clinics
- Others
Companies covered
- Astellas Pharma
- CSL
- Serum Institute Of India
- GlaxoSmithKline
- Pfizer
- Merck
- Johnson & Johnson
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Live Attenuated Vaccines Market Size (2021-2032)
- 2.2.2 Global Live Attenuated Vaccines Sales (2021-2032)
- 2.2.3 Global Live Attenuated Vaccines Market Average Price (2021-2032)
- 2.3 Live Attenuated Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Bacterial
- 2.3.3 Viral
- 2.4 Live Attenuated Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Institutes
- 2.4.3 Hospitals
- 2.4.4 Clinics
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Live Attenuated Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Live Attenuated Vaccines Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Live Attenuated Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Live Attenuated Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Live Attenuated Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Live Attenuated Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Live Attenuated Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Live Attenuated Vaccines, Established Date
- 3.9 Global Live Attenuated Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Astellas Pharma
- 4.1.1 Astellas Pharma Company Information
- 4.1.2 Astellas Pharma Business Overview
- 4.1.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
- 4.1.5 Astellas Pharma Recent Developments
- 4.2 CSL
- 4.2.1 CSL Company Information
- 4.2.2 CSL Business Overview
- 4.2.3 CSL Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSL Live Attenuated Vaccines Product Portfolio
- 4.2.5 CSL Recent Developments
- 4.3 Serum Institute Of India
- 4.3.1 Serum Institute Of India Company Information
- 4.3.2 Serum Institute Of India Business Overview
- 4.3.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
- 4.3.5 Serum Institute Of India Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Live Attenuated Vaccines Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Merck
- 4.6.1 Merck Company Information
- 4.6.2 Merck Business Overview
- 4.6.3 Merck Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Merck Live Attenuated Vaccines Product Portfolio
- 4.6.5 Merck Recent Developments
- 4.7 Johnson & Johnson
- 4.7.1 Johnson & Johnson Company Information
- 4.7.2 Johnson & Johnson Business Overview
- 4.7.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
- 4.7.5 Johnson & Johnson Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Live Attenuated Vaccines Product Portfolio
- 4.8.5 Sanofi Recent Developments
5 Global Live Attenuated Vaccines Market Scenario by Region
- 5.1 Global Live Attenuated Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Live Attenuated Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Live Attenuated Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Live Attenuated Vaccines Sales by Region: 2027-2032
- 5.3 Global Live Attenuated Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Live Attenuated Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Live Attenuated Vaccines Revenue by Region: 2027-2032
- 5.4 North America Live Attenuated Vaccines Market Facts & Figures by Country
- 5.4.1 North America Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Live Attenuated Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Live Attenuated Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Live Attenuated Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Live Attenuated Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Live Attenuated Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Live Attenuated Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Live Attenuated Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Live Attenuated Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Live Attenuated Vaccines Market Facts & Figures by Country
- 5.7.1 South America Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Live Attenuated Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Live Attenuated Vaccines Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Live Attenuated Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Live Attenuated Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Live Attenuated Vaccines Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Live Attenuated Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Live Attenuated Vaccines Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Live Attenuated Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Live Attenuated Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Live Attenuated Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Live Attenuated Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Live Attenuated Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Live Attenuated Vaccines Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Live Attenuated Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Live Attenuated Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Live Attenuated Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Live Attenuated Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Live Attenuated Vaccines Value Chain Analysis
- 8.1.1 Live Attenuated Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Live Attenuated Vaccines Production Mode & Process
- 8.2 Live Attenuated Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Live Attenuated Vaccines Distributors
- 8.2.3 Live Attenuated Vaccines Customers
9 Global Live Attenuated Vaccines Analyzing Market Dynamics
- 9.1 Live Attenuated Vaccines Industry Trends
- 9.2 Live Attenuated Vaccines Industry Drivers
- 9.3 Live Attenuated Vaccines Industry Opportunities and Challenges
- 9.4 Live Attenuated Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst